openPR Logo
Press release

Irritable Bowel Syndrome (IBS) Treatment Market: Increasing Prevalence of Irritable Bowel Syndrome and Associated Conditions

07-09-2021 01:15 PM CET | Health & Medicine

Press release from: The Insight Partners

Irritable Bowel Syndrome (IBS) Treatment Market

Irritable Bowel Syndrome (IBS) Treatment Market

The major factors such as the increasing prevalence of irritable bowel syndrome diseases and rising research & development activities drive the market growth. However, the limited number of product availability and treatment inefficiency restrain the market growth. IBS is a common chronic condition that affects the abdominal organ, large intestine. It is also known as spastic colon, mucous colitis, irritable colon, and spastic colitis. The condition is much different than inflammatory bowel disease. It shows symptoms such as cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both at the same. If the symptoms are mild, they can be managed by changing stress, lifestyle, and diet. On the other side, severe symptoms are treated with medication and counseling.

The irritable bowel syndrome (IBS) treatment market was valued at US$ 2,153.89 million in 2020 and is projected to reach US$ 4,600.30 million by 2028; it is expected to grow at a CAGR of 10.1% from 2021 to 2028.

Request for sample research at: https://www.theinsightpartners.com/sample/TIPRE00006814/?openpr-10144

Ironwood Pharmaceuticals, Inc.; AbbVie.; Sebela Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Alfasigma S.p.A.; Astellas Pharma Inc.; AstraZeneca; Synthetic Biologics, Inc.; Bausch + Lomb Incorporated; and Lannett Company Inc are among the leading companies operating in the market.

Based on type, the irritable bowel syndrome (IBS) treatment market is segmented into mixed IBS (IBS-M), IBS with diarrhea (IBS-D), and IBS with constipation (IBS-C). The mixed IBS (IBS-M) segment held the largest share of the market in 2020. Also, the same segment is expected to register the highest CAGR during 2021–2028. In the coming years, the rising prevalence of IBS among women and men is anticipated to propel the demand for the medicines that can treat combined symptoms of constipation and diarrhea. According to updated Rome IV criteria, the reverse condition of IBS-M is described as a model of hard or irregular stools in more than 25% of bowel movements. The prevalence is higher in the geriatric population. Therefore, the demand for medicines to treat mixed IBS is likely to grow significantly during the forecast period,

Irritable bowel syndrome is a majorly observed chronic gastrointestinal condition that is caused due to disturbances in bowel habits and abdominal pain. The disease is also known as spastic colon, irritable colon, mucous colitis, and spastic colitis. Irritable bowel syndrome shows symptoms such as abdominal pain, constipation, diarrhea, and cramping. Health systems across the regions are witnessing considerable growth in the incidence of irritable bowel syndrome. A data published by International Foundation for Gastrointestinal Disorders states that among all IBS patients, about 40% patients have mild IBS, around 35% have moderate IBS, and an estimated 25% suffer from severe IBS. Many people don't recognize IBS symptoms.

Certain factors such as food allergies, developing stages of gastroenteritis, sporadic movements of colon, abnormal composition of serotonin in colon, and mild celiac disease are among the risk factors that can cause IBS. These factors are projected to accelerate the rate of IBS prevalence across the world. For instance, according to a study published on NCBI in 2018, IBS is estimated to affect around 10% to 16% of the US population each year. Such staggering prevalence of IBS is likely to boost the irritable bowel syndrome (IBS) treatment market during the forecast period.

Purchase Full copy of This Report at: https://www.theinsightpartners.com/buy/TIPRE00006814/?openpr-10144

Irritable Bowel Syndrome (IBS) Treatment Market – by Type

IBS with Diarrhea (IBS-D)
IBS with Constipation (IBS-C)
Mixed IBS (IBS-M)
Irritable Bowel Syndrome (IBS) Treatment Market – by Product

Rifaximin
Eluxadoline
Linaclotide
Lubiprostone
Others
Irritable Bowel Syndrome (IBS) Treatment Market – by Distribution Channel

Hospitals Pharmacies
Drug Stores and Retail Pharmacies
Online Pharmacies

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us
Phone: +1-646-491-9876
Email- sales@theinsightpartners

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Irritable Bowel Syndrome (IBS) Treatment Market: Increasing Prevalence of Irritable Bowel Syndrome and Associated Conditions here

News-ID: 2325187 • Views:

More Releases from The Insight Partners

Encapsulation Resins Market Growing Rapidly with Recent Trends and Outlook By 2031
Encapsulation Resins Market Growing Rapidly with Recent Trends and Outlook By 20 …
The latest report, titled "Global Encapsulation Resins Market Share, Size and Trends | 2031", by The Insight Partners offers a comprehensive analysis of the Encapsulation Resins market, which comprises insights based on an in-depth Encapsulation Resins market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the global market. The Encapsulation Resins market has been growing significantly in recent years, driven by many key factors, such as
Extruded Plastics Market Growth with Worldwide Industry Analysis to 2031
Extruded Plastics Market Growth with Worldwide Industry Analysis to 2031
The latest "Extruded Plastics Market Forecast | Share and Size - 2031" report by The Insight Partners offers a detailed analysis of prime factors that impact the market growth such as key market players, current market developments, and pivotal trends. The report includes an in-depth study of key determinants of the global market including drivers, challenges, restraints, and upcoming opportunities. This market report is ideal for businesses opting to enter or
Mesenchymal Stem Cells Market Is Gaining Huge Growth In Upcoming Years
Mesenchymal Stem Cells Market Is Gaining Huge Growth In Upcoming Years
Mesenchymal Stem cells (MSCs) are stromal cells that have the ability to self-renew and also exhibit multilineage differentiation. It can be isolated from a variety of tissues, such as the umbilical cord, endometrial polyps, menses blood, bone marrow, adipose tissue, etc. It is most preferred cell type for regenerative medicine that used to treat neurological disorders, cardiac ischemia, diabetes, and bone and cartilage diseases. Get Exclusive Sample Copy of This Report
Automotive Paints Market SWOT Analysis, Dynamics, Drivers, Key Indicators and Forecast to 2031
Automotive Paints Market SWOT Analysis, Dynamics, Drivers, Key Indicators and Fo …
The latest "Automotive Paints Market Forecast | Share and Size - 2031" report by The Insight Partners offers a detailed analysis of prime factors that impact the market growth such as key market players, current market developments, and pivotal trends. The report includes an in-depth study of key determinants of the global market including drivers, challenges, restraints, and upcoming opportunities. This market report is ideal for businesses opting to enter or

All 5 Releases


More Releases for IBS

Integrated Bridge Systems Market Report 2018: Segmentation by Platform (Commerci …
Global Integrated Bridge Systems market research report provides company profile for Northrop Grumman Sperry Marine (U.K.), Raytheon Anschütz (Germany), Rolls Royce (U.K.), L-3 Communications Mapps Inc. (Canada), FURUNO Electric Shokai Ltd. (Japan) and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR
IBS' solution to power China’s first Cruise Line
Trivandrum, 16 January 2013: Henna, the largest cruise ship in mainland China will run on IBS’ inventory and pricing management solution, Cruise Partner, when it makes its maiden journey on January 26, 2013. China based HNA Tourism Cruise and Yacht Management Company unveiled this cruise ship on November 28, 2012. Henna has 739 rooms for 1,965 passengers, as well as a complete range of facilities for living and entertainment. HNA
Vikash Sureka joins IBS as Chief Financial Officer
Trivandrum (India), 17 May 2012: IBS Software Services, the leading provider of new-generation IT solutions to the global aviation industry, has appointed Mr Vikash Sureka as its Chief Financial Officer. He will head the Finance, Legal, Company Affairs and Administration functions of IBS operations world-wide. A Chartered Accountant, Vikash has over 19 years of experience mostly in senior executive roles managing business globally with proven proficiency in Investor Relations, P&L
HaCon and IBS combine expertise in railway operation
Hanover (2010-07-06). Two Hanoverian companies now combine their expertise in questions of railway operations: With effect from 1 July 2010, the HaCon Ingenieurgesellschaft mbH, took over the engineering firm for railway operating systems (Ingenieurbüro für Bahnbetriebssysteme GmbH – IBS). This way HaCon expanded its services to include the areas operation simulation, vehicle and personnel planning and construction operations planning. This also includes consulting services concerning railway systems issues, such as travel
Raytheon Anschütz IBS for new Intership Bulkers
Raytheon Anschütz was recently awarded a contract to supply their Integrated Bridge System (IBS) to two new bulk carriers. The bulkers will be built at New Times Shipyard in Jingjiang, China. The delivery to the Cyprus based shipping company Intership Navigation Co. Ltd., a member of the German Hartmann Group, is scheduled for August and October 2011. The new bulkers, each with a capacity of 176,000 dwt, will be equipped
CoCoNet enhances MULTIVERSA IBS by OFTP access protocol
CoCoNet enhances the modern e-banking-platform MULTIVERSA IBS International Banking Server through an OFTP access channel (Odette File Transfer Protocol) for the data transmission between international banks and corporate customers. MULTIVERSA IBS is a modular and scalable platform for receiving and processing payment transaction data and delivering customer specific account information like account statements, intraday reports, returns and foreign exchange rate information. The initial situation at banks that now also offer